The legal nature of VBP — government-led bulk procurement

Volume-Based Procurement uses national or provincial-alliance purchasing power to select winners through open bidding — volume for price. Its legal nature is dual:

  • Administrative drive: organised by NHSA and provincial bureaus, with procurement catalogues, bidding rules and award criteria set by the administration.
  • Civil contract: the resulting supply contracts between the winner and hospitals (or provincial platforms) are civil contracts governed by the Civil Code.

This duality means a winning company faces both administrative sanctions (violation list, loss of eligibility) and contractual liability (damages to hospitals).

Core bid-compliance requirements

Bid qualifications — the "entry ticket"

  • A China drug registration certificate (NDA or ANDA)
  • Passed GMP conformity inspection
  • Company and product information declared on the national procurement platform
  • No quality-related recall or sales suspension by the drug authority
  • No current "violation list" status from a prior VBP default

Bid-price constraints and legal risk

  • Price ceiling: bids may not exceed the lowest listed price on any provincial procurement platform (the "national lowest-price" rule).
  • Bid-rigging — criminal risk: price alliances, territory allocation or rotating wins among bidders constitute monopolistic agreements (Anti-Monopoly Law) and the crime of bid-rigging (Criminal Law Art. 223) — up to 3 years for responsible individuals.
  • Below-cost dumping: a bid below cost that cannot be sustained invites supply-default risk, and sustained below-cost selling may be treated as unfair competition.

Practical advice: lower is not always better. Cost the bid fully — production, regional logistics, platform service fees, packaging changes (VBP often requires standardised packaging) and possible returns — to ensure the price is commercially sustainable.

Core post-award obligations

Supply security — the hard "volume" constraint

  • Contract volume: supply the agreed quantity (typically 60–80% of declared hospital demand) without reduction.
  • Coverage: cover all public hospitals in the awarded region, including remote primary-care facilities — no selective supply.
  • Safety stock: maintain stock above the agreed volume to absorb raw-material or line disruptions.

Quality security — the hard "quality" constraint

  • Quality must not fall below the standard declared at bidding.
  • No unauthorised changes to raw-material source, excipient grade or production site (changes need prior approval/filing).
  • VBP-awarded drugs are priority targets for GMP unannounced inspection and market sampling.

Consequences of default — "triple punishment"

DefaultAdministrative sanctionContractual liability
Supply failureViolation list → loss of VBP eligibility for all products for 1–2 years → public notice.Damages to hospitals (based on undelivered value).
Quality failureCancellation of award → violation list → recall → GMP inspection → possible revocation of the registration certificate.Return/exchange and damages to hospitals.
Selective supplyWarning → ordered remediation → violation list.Damages to hospitals in unsupplied areas.
Unauthorised subcontractingCancellation of award → violation list → possible GMP investigation.Contract invalidation and liability.

Pricing for products outside VBP

  • Post-patent-cliff pricing: originals that lose VBP to generics can still sell in retail and self-pay channels, but face "reference pressure" from VBP and generic prices.
  • Brand-premium strategy: some originals stay out of VBP to preserve brand pricing for the self-pay/high-end market — provided pricing is not "price fraud" or "unfairly high".
  • Channel differentiation: managing hospital (VBP), pharmacy and online price differences to avoid "price inversion" and regulatory scrutiny.

How we help

  1. Pre-bid compliance review: qualification checks, legal-risk assessment of the bid price, and information firewalls against bid-rigging.
  2. Post-award contract management: review of platform supply contracts and the raw-material → production → logistics chain.
  3. Default-risk assessment: supply-capacity stress tests, raw-material risk assessment and contingency planning.
  4. Penalty response: appeals and administrative reconsideration after listing, and handling contractual disputes with hospitals.